ストックスクリーナーアプリを入手
19.88
0.30%
-0.06
アフターアワーズ：
20.00
0.12
+0.60%
前日終値:
$19.94
開ける：
$19.64
24時間の取引高:
438.90K
Relative Volume:
1.17
時価総額：
$589.80M
収益：
$17.16M
当期純損益:
$-163.62M
株価収益率:
-3.8304
EPS:
-5.19
ネットキャッシュフロー:
$-121.61M
1週間 パフォーマンス:
-35.45%
1か月 パフォーマンス:
-41.49%
6か月 パフォーマンス:
-25.21%
1年 パフォーマンス:
+13.41%
1日の値動き範囲:
$19.00
$19.93
1週間の範囲:
$19.00
$25.41
52週間の値動き範囲:
$13.36
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
名前
Anaptysbio Inc
セクター
電話
858-362-6295
住所
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-05-22 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-05-18 | 開始されました | TD Cowen | Outperform |
| 2023-01-06 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-09-19 | 再開されました | H.C. Wainwright | Buy |
| 2022-09-13 | ダウングレード | Truist | Buy → Hold |
| 2022-09-01 | 開始されました | Raymond James | Outperform |
| 2022-03-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-06-22 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-21 | 開始されました | UBS | Neutral |
| 2021-03-16 | アップグレード | Truist | Hold → Buy |
| 2021-03-09 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-03-08 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2021-02-11 | アップグレード | JP Morgan | Underweight → Overweight |
| 2020-10-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-10-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-08 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2019-11-08 | ダウングレード | Jefferies | Buy → Hold |
| 2019-11-08 | ダウングレード | SunTrust | Buy → Hold |
| 2019-11-08 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-06-21 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | ダウングレード | Stifel | Buy → Hold |
| 2018-12-20 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-21 | 開始されました | JP Morgan | Overweight |
| 2018-07-19 | 開始されました | Credit Suisse | Outperform |
| 2018-04-04 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | 繰り返されました | Stifel | Buy |
| 2018-03-06 | 繰り返されました | Stifel | Buy |
| 2018-02-15 | 繰り返されました | SunTrust | Buy |
| 2018-01-23 | 繰り返されました | Credit Suisse | Outperform |
| 2017-11-15 | 開始されました | SunTrust | Buy |
| 2017-11-09 | 開始されました | Jefferies | Buy |
| 2017-10-11 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Anaptysbio Inc (ANAB) 最新ニュース
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Anaptys Announces Participation in November and December Investor Conferences - The Manila Times
AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.4%Should You Sell? - MarketBeat
Things To Consider Before Buying AnaptysBio Inc (NASDAQ: ANAB) - Stocks Register
AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs (NASDAQ:ANAB) - Seeking Alpha
AnaptysBio (ANAB) Shares Plunge as Eli Lilly Ends Arthritis Drug Research - GuruFocus.com
AnaptysBio (NASDAQ:ANAB) Given "Buy" Rating at HC Wainwright - MarketBeat
(ANAB) Trading Advice - Stock Traders Daily
AnaptysBio (NASDAQ:ANAB) Shares Gap DownWhat's Next? - MarketBeat
AnaptysBio (NASDAQ:ANAB) PT Raised to $33.00 - MarketBeat
AnaptysBio plunges as Eli Lilly drops co's arthritis drug from pipeline - XM
AnaptysBio stock falls as Lilly updates pipeline (ANAB:NASDAQ) - Seeking Alpha
O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - TradingView
Assenagon Asset Management S.A. Grows Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Trading Down 6.9%Here's Why - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Receives $54.64 Consensus Price Target from Analysts - MarketBeat
AnaptysBio (NASDAQ:ANAB) PT Raised to $90.00 - Defense World
nVerses Capital LLC Buys 1,400 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Guggenheim reiterates buy rating on AnaptysBio stock, sees favorable risk/reward ahead of December readout - Investing.com Canada
A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts - Benzinga
AnaptysBio (NASDAQ:ANAB) PT Raised to $90.00 at Guggenheim - MarketBeat
(ANAB) On The My Stocks Page - Stock Traders Daily
AnaptysBio (NASDAQ:ANAB) Shares Down 4.9%Here's Why - MarketBeat
Piper Sandler reiterates stock target, overweight on AnaptysBio post-UEGW By Investing.com - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Trading 6.5% HigherStill a Buy? - MarketBeat
Antibody Library Technology Market Report to 2032 -AnaptysBio Inc, MorphoSys AG, XOMA Corporation, Abzena Plc, AvantGen – IndiaPolitics.com - IndiaPolitics.com
RCM Technologies, Inc. (NASDAQ:RCMT) Shares Sold by Squarepoint Ops LLC - Defense World
Objective long/short (ANAB) Report - Stock Traders Daily
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Millennium Management LLC - MarketBeat
Dimensional Fund Advisors LP Has $8.42 Million Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Point72 Asset Management L.P. Decreases Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Down 3.2%Should You Sell? - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Down 3.2% – Time to Sell? - Defense World
AnaptysBio shares hold as Piper Sandler keeps Overweight rating By Investing.com - Investing.com Canada
Susquehanna Fundamental Investments LLC Has $1.81 Million Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Anaptysbio BTLA agonist reduces atopic dermatitis inflammation - BioWorld Online
Frazier Life Sciences Management L.P. Has $54.27 Million Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by Ensign Peak Advisors Inc - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Receives $51.10 Consensus Target Price from Analysts - MarketBeat
Wedbush Reaffirms Outperform Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
What Analysts Are Saying About AnaptysBio Stock - Benzinga
AnaptysBio Insiders Selling US$3.6m In Stock Relieved As Market Cap Slides To US$1.1b - Simply Wall St
Alpha DNA Investment Management LLC Takes Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Alpha DNA Investment Management LLC Invests $399,000 in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio chief medical officer sells shares worth over $58,000 By Investing.com - Investing.com Australia
AnaptysBio chief medical officer sells shares worth over $58,000 - Investing.com
Daily Progress: Adaptive Biotechnologies Corp (ADPT) Drop -8.39, Closing at 4.26 - The Dwinnex
Mount Yale Investment Advisors LLC Reduces Stake in ServiceNow, Inc. (NYSE:NOW) - Defense World
Applied Dna Sciences Inc (APDN) Stock: A Year of Market Fluctuations - The InvestChronicle
The ADPT Stock Puzzle: Unraveling Adaptive Biotechnologies Corp’s Fluctuating Performance - The InvestChronicle
APi Group Co. (NYSE:APG) Shares Sold by Progeny 3 Inc. - MarketBeat
Anaptysbio Inc (ANAB) 財務データ
収益
当期純利益
現金流量
EPS
Anaptysbio Inc (ANAB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lizzul Paul F. | Chief Medical Officer |
Sep 23 '24 |
Sale |
38.67 |
1,500 |
58,005 |
15,398 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):